EZH2 in Bladder Cancer, a Promising Therapeutic Target.

Abstract

Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the pathogenesis of these tumors. Among the epigenetic alterations, histone modifications occupied a central role not only in cancer, but also in normal organism homeostasis and development. EZH2 (Enhancer of Zeste Homolog 2) belongs to the Polycomb repressive complex 2 as its catalytic subunit, which through the trimethylation of H3 (Histone 3) on K27 (Lysine 27), produces gene silencing. EZH2 is frequently overexpressed in multiple tumor types, including BC, and plays multiple roles besides the well-recognized histone mark generation. In this review, we summarize the present knowledge on the oncogenic roles of EZH2 and its potential use as a therapeutic target, with special emphasis on BC pathogenesis and management.

DOI: 10.3390/ijms161126000

Extracted Key Phrases

3 Figures and Tables

010203020162017
Citations per Year

Citation Velocity: 11

Averaging 11 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{MartnezFernndez2015EZH2IB, title={EZH2 in Bladder Cancer, a Promising Therapeutic Target.}, author={M{\'o}nica Mart{\'i}nez-Fern{\'a}ndez and Carolina Rubio and Cristina Segovia and Fernando F. L{\'o}pez-Calder{\'o}n and Marta G Due{\~n}as and Jes{\'u}s M. Paramio}, journal={International journal of molecular sciences}, year={2015}, volume={16 11}, pages={27107-32} }